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Canada.BACKGROUND The Medtronic Attain Performa quadripolar leads
provide 16 pacing vectors with steroid on every electrode. This includes
a short bipolar conﬁguration between the middle 2 electrodes.
OBJECTIVE A prospective clinical study was conducted to inves-
tigate the safety and effectiveness of these new leads in 27
countries.
METHODS Cardiac resynchronization therapy with deﬁbrillator
candidates were enrolled (mean age 68 years; 71% men). All
implanted subjects were followed at 1, 3, and 6 months postim-
plant. Pacing capture threshold (PCT) values were measured at each
visit. Adverse events were reported upon occurrence.
RESULTS Of 1124 subjects in whom a left ventricular (LV) lead was
attempted, 1097 (97.6%) were successfully implanted with an
Attain Performa lead. Thirty-six LV lead-related complications were
reported (the 6-month LV lead-related complication-free survival
rate was 96.9%). Phrenic nerve stimulation (PNS) occurred in 81
subjects (7.2%), with only 3 (0.3%) requiring surgical intervention.
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programming polarities were used in at least 1 patient, and short
bipolar conﬁgurations were used in 17% of subjects.
CONCLUSION This large multicenter study demonstrated a high
success rate for the implantation of Attain Performa quadripolar LV
leads with a low complication rate. The PCT was low and stable over
time. A low rate of postimplantation PNS was observed, and cases
of PNS were readily resolved with reprogramming. Nonstandard
vectors were often used for LV pacing.
KEYWORDS Cardiac resynchronization therapy; Quadripolar lead;
Deﬁbrillator; Congestive heart failure
ABBREVIATIONS CRT ¼ cardiac resynchronization therapy; CRT-D
¼ cardiac resynchronization therapy with deﬁbrillator; LV ¼ left
ventricular; PCT ¼ pacing capture threshold; PNS ¼ phrenic nerve
stimulation; NYHA ¼ New York Heart Association
(Heart Rhythm 2015;12:751–758) I 2015 Heart Rhythm Society.
Open access under CC BY-NC-ND license.Introduction
Cardiac resynchronization therapy (CRT) improves heart
failure symptoms and mortality in patients with systolic heart
failure and a prolonged QRS duration.1–5 The successful
achievement of a stable and effective left ventricular (LV)
lead position is critical to the success of CRT.6–8 An
important limiting factor in the implementation of successful
CRT are often the variations and limitations of the anatomy
of the coronary veins and the position of the cardiac veins
relative to the phrenic nerve.5,9–14 Lead movement afterhttp://dx.doi.org/10.1016/j.hrthm.2014.12.019
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patient posture are challenges that we face. In fact, a 12% rate
of CRT failure postoperatively related to either loss of LV
capture or PNS has been reported.15 With a typical unipolar
or bipolar LV lead, resolution of these problems often
requires surgical intervention with the attendant risks and
costs of these procedures.16 LV leads with more than 2
electrodes have been developed to allow for additional
reprogramming options of the pacing vectors to help manage
these problems.10–12,17–20 These leads have been demon-
strated to reduce LV lead-related complications at the time of
implantation. (Data were orally presented in a late-breaking
session at the 2014 European Congress of Cardiology.)Methods
Device description
The Attain Performa quadripolar leads (Medtronic, Inc,
Minneapolis, MN) feature steroid on all 4 LV pacing
electrodes with a 21-mm spacing between the ﬁrst and
second electrodes and between the third and fourth electro-
des and a 1.3-mm spacing between the second and third
electrodes. These leads are intended to be placed into
tributaries of the coronary sinus for the provision of CRT.
Figure 1 displays the 3 shapes that were developed as a
family of Attain Performa LV leads. Model 4298 (Figure 1A)
is canted with a compound curve at the distal end; model
4398 (Figure 1B) is the straight lead with tines; and model
4598 (Figure 1C) has an offset S-shaped curve at the distal
end. All 3 lead models are constructed with an IS4 connector
and have 5.3-F proximal and 3.9-F distal lead body
diameters. The leads were implanted with market-released
implantation tools and compatible Medtronic Quad CRT-D
(cardiac resynchronization therapy with deﬁbrillator) pulse
generators (Viva Quad C, Viva Quad XT, Viva Quad S, and
Brava Quad), which can be programmed to use any of the 16
different pacing polarities for LV stimulation. The narrow-
spaced electrodes, “short bipolar,” were designed to reduceFigure 1 (A) Model 4298 canted lead, (B) model 4398 straight lead, and
(C) model 4598 S-shaped lead (Medtronic). The straight lead is tined. In
each lead, the interelectrode distance is 21 mm between the ﬁrst and second
electrodes and between the third and fourth electrodes. The interelectrode
distance between the second and third electrodes is 1.3 mm.the chance of stimulation of the phrenic nerve without
compromising pacing capture thresholds (PCTs).21
The VectorExpress feature of the accompanying pulse
generator allows for automatic and rapid testing of the PCT
and impedance for all possible vectors. This is usually
accomplished in less than 3 minutes. There is no negative
impact on battery drain associated with VectorExpress
because the time required for running VectorExpress is
shorter than that required for manual tests. This unique
feature also provides relative device longevity estimates for
different pacing conﬁgurations on the basis of both the
threshold and the impedance. The test results may be used to
help the clinicians determine which LV lead pacing polarity
is most appropriate for their patient, balancing the current
drain against the desired anatomic location.
Study design
This was an open-label, prospective, multicenter, clinical
trial designed to assess the safety and effectiveness of the
Attain Performa lead family (ClinicalTrials.gov ID:
NCT01751022). The trial began with the ﬁrst enrollment
in January 2013 and completed enrollment in January 2014.
The study was approved by the local governing research
authorities (institutional review board, ethics committee,
etc). CRT-D implantation candidates were enrolled on the
basis of local indications. All subjects gave written informed
consent.
All implanted subjects were followed at 1, 3, and 6
months and then every 6 months postimplant. PCT values
were measured using either manual or automated testing
method. Adverse events were reported upon occurrence and
reviewed by an independent physician committee.
Implantation procedure
Any market-released catheter system used for gaining
coronary sinus access and compatible with the Attain
Performa lead could be used. Coronary sinus venography
was required before LV lead placement. The lead choice was
determined by the implanting physician on the basis of the
visualization of the coronary veins and implanting/lead
handling experience, but it was also limited by the avail-
ability of various lead models. In geographies where Attain
Performa leads were not yet market released, the canted lead
was available early in the study and the other 2 models were
included later. If the Attain Performa lead was not attempted
or could not be implanted, any market-released LV lead
could be used.
Follow-up
Lead performance and subject heart failure status were
assessed; data were collected at the baseline visit, implant,
1, 3, and 6 months, and then every 6 months until market
release in the United States. The study protocol did not
require any speciﬁc programmed parameters. A substudy
was conducted to conﬁrm VectorExpress measure-
ment accuracy against traditional manual tests. Paired
753Crossley et al Short Bipolar Quadripolar Leadsmeasurements were collected from the ﬁrst 62 consecutively
enrolled subjects.
Study end points
The effectiveness of the lead was evaluated by estimating the
probability of a subject having a ﬁnal programmed LV
pacing polarity with a PCT ofr2.5 V with no PNS present
at that value. It was assumed that a well-performing LV lead
would minimally achieve a success rate greater than 80% (ie,
the 95% conﬁdence interval lower bound would be480%).
The primary safety end point was Attain Performa LV lead-
related complications. Historical clinical studies indicate that
the LV lead complication rate postimplantation often ranges
between 6% and 8%.22,23
Statistical analysis
To evaluate the primary efﬁcacy end point, success was
determined for each patient on the basis of the PCT value and
PNS threshold (if present) at the 6-month follow-up visit for
each subject with a functioning Attain Performa lead. Survival
analysis was used to evaluate the primary safety end point as a
function of time postimplantation. All subjects who under-
went an Attain Performa LV lead implantation attempt were
included in the analysis. All reported system or implantation
procedure–related events were reviewed by an independent
physician panel and classiﬁed for relatedness to system
component and/or procedure, and severity (complication vs
observation). A complication was deﬁned as any adverse
event that was resolved by invasive treatment or resulted in
patient death or loss of signiﬁcant functionality of device
therapy.
Secondary end points
The occurrence of PNS in all the LV lead pacing polarities
at the maximum device output of 8 V was evaluated at
implantation as well as at follow-up visits. PNS occurrenceFigure 2 Enrollmrates at the 2 short bpolar conﬁgurations were compared with
those of the remaining conﬁgurations by using the generalized
estimating equation models to account for within-subject
correlations. At the 6-month visit, the PNS threshold was
measured when PNS was detected at 8 V. Implantation
success rate, implantation procedure duration, and lead
handling characteristics were summarized using descriptive
statistics. Device system components and/or implantation
procedure–related adverse events were summarized as obser-
vations vs complications and the event type by using the
Medical Dictionary for Regulatory Activities. Clinical out-
comes including death, heart failure–related hospitalization,
New York Heart Association (NYHA) functional class, and
patient global assessment were obtained.Results
Patient population
A total of 126 centers in 27 countries from North America,
Europe, Australia, Asia, the Middle East, Africa, and South
America enrolled a total of 1201 patients. Of those, 46
patients did not undergo an implantation procedure and were
subsequently excluded from the study. Of the 1155 subjects
who underwent implantation procedures, 1124 attempted
Attain Performa leads, and 1097 of the 1124 subjects
(97.6%) were successfully implanted with an Attain Per-
forma lead. The distribution of enrolled subjects is shown in
Figure 2. As of May 2014, Attain Performa lead recipients
were followed for an average of 6.6 2.8 months. The mean
age of patients who underwent implantation procedures was
68  11 years, 71% were men, and 74% were whites. Most
patients were either NYHA class II (27%) or NYHA class III
(68%). The mean LV ejection fraction was 27%  7%. The
mean QRS duration was 156  23 ms. Left bundle branch
block was reported in 72% of patients. There were no
signiﬁcant differences in these clinical characteristics among
patients receiving different lead models.ent ﬂowchart.
Figure 3 Percentage of patients with a PCT of r2.5 V for each lead.
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Implanting physicians rated the LV lead handling as accept-
able in 98.8% of the cases on the basis of a questionnaire
completed after each implantation procedure. LV lead
implant times averaged 14  19 minutes.Electrical performance
The overall percentage of patients with a PCT of r2.5 V
without PNS at the stimulation voltage was 95.3%, and it
was similar for all 3 leads (Figure 3). The mean PCT at the
ﬁnal programmed vector was (1.1  0.8) V at the 6-month
postimplantation visit. Table 1 presents the mean PCTs over
time. A wide array of the ﬁnal programmed vectors was
chosen (Table 2). The majority of the ﬁnal chosen vectors
were those that were not previously available with a unipolar
or a standard Medtronic bipolar lead system. Speciﬁcally at 6
months, 17% subjects were programmed to LV1 to RV coil,
18% were programmed to LV1 to LV2, 7% wereTable 1 Mean pacing capture thresholds (volt) at the ﬁnal programme
Visit
Model 4298 Model 4398
n Mean  SD n Mean 
Implantation 482 1.2  0.9 316 1.3  1
Month 1 468 1.1  0.8 305 1.2  0
Month 3 429 1.1  0.7 287 1.2  0
Month 6 429 1.1  0.7 266 1.1  0programmed to LV2 to RV coil, 4% were programmed to
LV2 to LV1, and 54% used other pacing polarities. The
distribution of PCT and mean PNS threshold (if present) by
polarity at the 6-month visit is also given in Table 2. There
was
no difference in PCT between patients with ischemic
cardiomyopathy and those with non–ischemic cardiomyop-
athy (P ¼ .4).
Figure 4 displays the results of the high output pacing
test (ie, PNS at 8-V output) at the 6-month visit. The
occurrence of PNS for the 2 short bipolar vectors was
signiﬁcantly lower than that for the other pacing vectors
(64% relative reduction; Po .0001, generalized estimating
equation model estimate).Safety performance and adverse events
The primary safety end point, freedom from lead-related
complication, was 97% at both 3 and 6 months (95%d LV polarities at 0.5 ms
Model 4598 Combined
SD n Mean  SD n Mean  SD
.0 293 1.1  0.8 1091 1.2  0.9
.8 277 1.1  0.8 1050 1.1  0.8
.8 271 1.1  0.7 987 1.1  0.8
.8 265 1.1 0.8 960 1.1  0.8
Table 2 Attain Performa lead pacing capture thresholds at each polarity and ﬁnal conﬁguration
Polarity
Stimulation threshold (V) (pulse width ¼ 0.5 ms) PNS threshold (V)* Final conﬁguration
Implantation 6 mo 6 mo 6 mo
n Mean  SD n Mean  SD n* Mean  SD %
LV1 to RV coil 1066 1.2  1.2 946 1.0  0.9 413 3.7  2.3 16.6
LV1 to LV2 1044 1.6  1.4 934 1.4  1.1 368 4.1  2.2 17.7
LV1 to LV3 1045 1.7  1.4 937 1.4  1.0 369 4.1  2.2 4.4
LV1 to LV4 1032 1.7  1.4 936 1.4  1.1 342 4.0  2.3 5.2
LV2 to RV coil 1033 1.4  1.3 908 1.3  1.2 305 4.0  2.3 7.3
LV2 to LV1 999 2.0  1.4 904 1.7  1.3 305 4.5  2.0 4.0
LV2 to LV3 940 1.7  1.5 820 1.5  1.3 133 4.9  2.0 12.7
LV2 to LV4 972 1.9  1.4 876 1.8  1.4 241 4.3  2.0 4.8
LV3 to RV coil 1008 1.5  1.3 888 1.5  1.3 282 4.0  2.3 4.8
LV3 to LV1 988 2.1  1.4 894 1.9  1.3 312 4.8  2.1 2.0
LV3 to LV2 912 1.9  1.5 775 1.6  1.4 118 4.9  2.0 4.3
LV3 to LV4 960 2.1  1.5 842 1.9  1.4 225 4.3  2.1 6.6
LV4 to RV coil 803 2.4  1.7 683 2.1  1.5 192 4.6  2.3 6.7
LV4 to LV1 918 2.7  1.5 860 2.4  1.3 244 5.3  2.0 1.7
LV4 to LV2 857 2.8  1.6 750 2.6  1.4 191 5.1  2.0 0.2
LV4 to LV3 818 2.8  1.6 731 2.6  1.5 183 4.9  2.0 1.2
PNS ¼ phrenic nerve stimulation.
*Patients with PNS at 8-V output were further tested for PNS thresholds.
755Crossley et al Short Bipolar Quadripolar Leadsconﬁdence interval 96%–98%) and was similar for all 3 of
the lead models (Figure 5).
No unanticipated adverse events were reported. A total of
36 LV lead-related complications (3%) were reported among
the 1124 subjects who underwent an Attain Performa lead
implantation procedure. Lead dislodgement at the last clinic
visit was low (1.4%) in this study. It is notable that theFigure 4 Graph of the freedom from a left vestraight lead had a relatively lower dislodgement rate
compared to the other leads (0.3% in subjects with model
4398 lead vs 2.0% in subjects with model 4298 lead and
1.7% in subjects with model 4598 lead). The occurrence of
PNS was 7.2%; 97% of complications were resolved without
surgical intervention. The only 3 PNS complications (rate ¼
0.3%) were all resolved by replacing the LV lead withntricular (LV) lead–related complication.
Figure 5 Rate of phrenic nerve stimulation (PNS) with pacing at 8 V is signiﬁcantly less when the short bipolar electrodes are used. LV ¼ left ventricular;
RV ¼ right ventricular.
Heart Rhythm, Vol 12, No 4, April 2015756another Attain Performa lead. The LV lead-related adverse
events and observations are summarized in Table 3.
VectorExpress
PCT values were measured at the implantation/prehospital
discharge visit after a successful Attain Peforma LV lead
implantation. VectorExpress produced results for 790 of 992
possible vectors (80%). The most common reasons why
VectorExpress did not provide results for some vectors were
a high PCT, short or indistinguishable atrioventricular
intervals, competing rhythms, or detection of possible anodal
stimulation. Correlation between VectorExpress and manual
testing was high (r ¼ 0.94; P o .0001), with an estimated
bias (manual  VectorExpress) of 0.03 V.
Clinical outcome
The clinical composite score method of Packer24 was
adopted to assess CRT response rate at the 6-month visit.
Patients were only considered to have improved if, at the 6-
month postimplantation visit, they were alive, had not been
hospitalized, and experienced at least 1 NYHA functional
class improvement or reported favorable response in the
patient global assessment question. Patients are considered
worse if the patient experienced any of the following events:
death, heart failure–related hospitalization, worsening of
NYHA class, and/or global assessment by the 6-month visit.
Patients are considered unchanged if they were neither
improved nor worsened. We observed 80.4% of patients
improved, 14.1% of patients worsened, and 5.5% did not
change.
There were a total of 54 deaths (4.5%) during the study.
Of those deaths, 11 were classiﬁed as sudden cardiac (20%),
14 (26%) as non–sudden cardiac, and 24 (44%) as non-
cardiac. In 6 subjects, there was insufﬁcient information for
classiﬁcation. Three deaths occurred before implantationprocedures, 38 occurred in the ﬁrst 6 months, and 13
occurred after the 6-month visit.Discussion
The ultimate goal of LV lead placement is to ensure stable
LV stimulation at a desired pacing site. This could be
hindered by loss of LV capture in more than 10% of patients
because of LV dislodgement, PNS, or high LV thresh-
old.12–18,20,23,25,26 Achieving a low LV PCT at implanta-
tion reduces the likelihood of PNS and increases device
longevity. The PCT of these leads were low, with an
average of (1.2  0.9) V at implantation and (1.1  0.8)
V at 6 months at the ﬁnal programmed vector. The mean
PCT ranged from 1.0 to 2.6 V for all 16 conﬁgurations at
the 6-month visit. This result compares favorably to other
unipolar and bipolar leads29,30 and appears to be superior to
the other commercially available quadripolar leads31 where
nonstandard vectors provide stimulation thresholds greater
than 3 V on average. One distinctive construct of the Attain
Performa lead is that this lead has a steroid-eluting
monolithic controlled release device sleeve/ring at each of
the 4 electrodes. While it is well established that the
addition of steroid to endocardial leads signiﬁcantly
improves PCTs,32 the same effect was never previously
veriﬁed for leads placed in the tributaries of the coronary
sinus. The data presented here, as compared with the data
on the other market-released quadripolar leads, strongly
suggest that steroid elution may improve the performance
of all electrodes.27
With a low PCT, clinicians targeted more speciﬁc pacing
sites in proximal or basal regions that are associated with
enhanced patient outcomes as compared with apical pacing
sites, without compromising battery longevity. In addition,
the availability of VectorExpress allowed the opportunity to
evaluate 16 pacing vectors and choose a particular vector that
Table 3 Attain Performa lead–related adverse events
Event Model 4298 (n ¼ 499) Model 4398 (n ¼ 326) Model 4598 (n ¼ 299) Overall (n ¼ 1124)
Complications
Deep vein thrombosis 0/0 1/1 2/2 3/3
Device capturing issue* 2/2 1/1 0/0 3/3
Device connection issue 3/3 1/1 2/2 6/6
Lead dislodgement 10/10 1/1 5/5 16/16
Increased threshold 2/2 0/0 0/0 2/2
Extracardiac stimulation 1/1 2/2 0/0 3/3
Sepsis 1/1 0/0 0/0 1/1
Subclavian vein thrombosis 0/0 0/0 2/2 2/2
Total 19/19 6/6 11/11 36/36
Observations
Cardiac vein dissection 0/0 0/0 1/1 1/1
Deep vein thrombosis 2/2 1/1 2/2 5/5
Device damage 0/0 1/1 0/0 1/1
Impedance issue 0/0 1/1 0/0 1/1
Increased threshold 2/2 2/2 1/1 5/5
Extracardiac stimulation 36/32 35/29 21/20 92/81
Dyspnea 1/1 0/0 0/0 1/1
Superior vena cava stenosis 1/1 0/0 0/0 1/1
Ventricular dyssynchrony 1/1 0/0 0/0 1/1
Total 43/38 40/32 25/23 108/93
*The numbers represent the number of events and the number of patients
757Crossley et al Short Bipolar Quadripolar Leadswould be best for patients in a reasonable time during a
clinical visit.
During this clinical study, nonstandard vectors were
programmed more often than previously published reports
on quadripolar leads.27 We speculate that the high usage of
nonstandard vectors was due to the fact that most LV
polarities achieved low PCTs, and the unique short bipolar
conﬁgurations avoid PNS symptoms successfully. The PNS
rates elicited by the pacing test at 8 V (Figure 4) were lower,
and the PNS  PCT differences (Table 2) were wider at 6
months in the short bipolar conﬁgurations compared to other
pacing vectors.
Consistent with these ﬁndings and previous animal and
acute human studies,21,28 we observed a low incidence of
PNS symptoms (7%; Table 3). Bifﬁ and colleagues28
reported that in a group of 1307 patients with bipolar and
unipolar leads the incidence of PNS was 12.9%, while
Tomassoni et al27 reported a similar PNS event rate of
13.5% at 3-month follow-up by using another lead. Thus,
Attain Performa leads enhance PNS management at no
compromise with the LV capture threshold.
The overall implantation success with this system was
also favorable. The 97.6% successful implantation rate
compares favorably with previous studies, such as CARE-
HF (89%),29 the combined MIRACLE, MIRACLE ICD, and
InSync II (92%),30 Starﬁx (94%),31 and EASYTRAK
(88%).32,33 Implantation times have not been widely
reported for previous leads, but our results of 13.9  19
minutes compare favorably with the results reported by
others.27,31,34
Study limitations
This is an observational study that reports the results of these
leads alone. It is neither a randomized study comparingresults with those of unipolar or bipolar LV leads nor did it
evaluate physician’s choice of different models of the lead
family. However, the study performance criteria were
determined on the basis of the performance of previous
market-released LV leads.Conclusion
The Attain Performa LV leads, coupled with Quad CRT-D
devices, were demonstrated to be safe and effective. The suite of
technologies has the potential to enhance CRT delivery. It
includes 16 selectable pacing vectors that provide more options
for noninvasive postoperative treatment; a pair of short bipolar
conﬁgurations that reduce the incidence of PNS symptoms;
steroid elution on every electrode that achieves low pacing
thresholds for all pacing vectors during both acute and chronic
phases; and the VectorExpress software that provide clinicians
rapid and accurate measurements for all LV pacing conﬁgura-
tions, allowing for a more efﬁcient follow-up. This combination
allows physicians to deliver CRTwhile potentially increasing the
battery life and reducing the risk of reoperation for PNS.Acknowledgments
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By using this steroid-eluding quadripolar lead, we were able to achieve successful left ventricular pacing while maintaining
excellent pacing capture thresholds. This is in contrast to the existing quadripolar leads that demonstrate high thresholds on
the third and fourth electrodes. We also demonstrated that the use of the narrowly spaced pair of electrodes was associated
with a remarkable avoidance of phrenic nerve stimulation. By using this novel technology, physicians should be able to
accomplish efﬁcacious cardiac resynchronization therapy without sacriﬁcing thresholds and worsening longevity of the
pulse generator and without sacriﬁcing lead position for the sake of lead stability. Translation of these results into clinical
practice should be easy since the leads are now available in most geographies.
